Your browser doesn't support javascript.
loading
In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.
Cooper, Amy L; Greenberg, Victoria L; Lancaster, Pamela S; van Nagell, John R; Zimmer, Stephen G; Modesitt, Susan C.
Affiliation
  • Cooper AL; Division of Gynecologic Oncology, University of Kentucky Chandler Medical Center, Lexington, KY, USA.
Gynecol Oncol ; 104(3): 596-601, 2007 Mar.
Article in En | MEDLINE | ID: mdl-17049973
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Histone Deacetylase Inhibitors Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Gynecol Oncol Year: 2007 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Histone Deacetylase Inhibitors Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Gynecol Oncol Year: 2007 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos